Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
Voyageur Pharmaceuticals settles $192,000 of debt through an equity transaction to avoid insolvency.
Voyageur Pharmaceuticals Ltd. (VM) has proposed settling $192,300 in outstanding debts by issuing 1,240,644 common shares at a deemed price of $0.155 per share. The transaction allocates $52,300 to an officer, resulting in the issuance of 337,419 shares, while $140,000 is allocated to other creditors, resulting in 903,225 shares.
The company states the purpose of the transaction is to preserve its limited cash reserves. Classified as a related-party transaction under MI 61-101, the deal relies on exemptions from formal valuation and minority shareholder approval. The issued shares carry a 4-month and 1-day hold period and are subject to TSX Venture Exchange approval.
Voyageur Pharmaceuticals Ltd. (VM) issued shares as a routine liquidity management action to address a working capital deficit of $1.87M and a cash balance of only $75,709, based on prior-period context from Q1 2026. The transaction avoids immediate cash outflow but dilutes existing shareholders by approximately 0.69%, underscoring the company's reliance on equity-based debt settlements to maintain operations. The $0.155 settlement price is slightly above the recent trading range of $0.10–$0.17, which is marginally favorable to creditors but does not alter the fundamental cash burn trajectory. The announcement does not introduce new operational milestones, strategic partnerships, or changes to the company's development roadmap.
Voyageur Pharmaceuticals Ltd. (VM) is a pre-revenue Canadian company developing a vertically integrated supply chain for barium and iodine contrast media used in medical imaging. Its flagship projects include the Frances Creek barite project in British Columbia and a collaborative iodine extraction project in Oklahoma with Bayer AG. The company aims to produce pharmaceutical-grade barium sulfate and high-purity iodine domestically, reducing reliance on imported raw materials. Regulatory progress includes an FDA 505(b)(2) submission for barium contrast agents initiated in February 2026.